Skip to content

Ascentage Pharma

US · AAPG #3045 by market cap Listed 2025
11.97 -0.47 -3.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • Total institutional ownership rose 0.6 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
26.22% +0.56pp
Institutions
59
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund14.43%
Individual/Insider12.90%
Private Company10.44%
Sovereign Wealth Fund1.30%
Other60.88%

Top holders as of 2026-06-30

Takeda Pharmaceuticals International AG 6.61% · 6.08M sh
Dajun Yang 6.32% · 5.81M sh
HealthQuest Pharma Limited 3.83% · 3.52M sh
Ming Guo 3.60% · 3.31M sh
Vanguard Capital Management, LLC 3.35% · 3.08M sh
China Universal Asset Management Company Ltd. 2.96% · 2.72M sh
Shaomeng Wang 2.73% · 2.51M sh
BlackRock 1.46% · 1.34M sh
Morgan Stanley 1.73% · 1.59M sh
JPMorgan Chase & Co. 1.69% · 1.55M sh
Norges Bank Investment Management 1.30% · 1.20M sh
GF Fund Management Co., Ltd. 1.15% · 1.06M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

34 filings tracked · 6 buys · 0 sells

NameRoleStake
Dajun Yang Chairperson & CEO 6.32%
Ming Guo Co-Founder 3.60%
Shaomeng Wang Co-Founder, Chief Scientific Advisor & Non-Executive Director 2.73%
Yifan Zhai Chief Medical Officer 0.11%
Thomas Knapp General Counsel 0.10%
Jin Cao Head of Finance 0.01%
Marc Lippman Independent Non-Executive Director 0.01%
David Sidransky Lead Independent Non-Executive Director 0.01%
Wei Ren Independent Non-Executive Director 0.00%
Changqing Ye Independent Non-Executive Director 0.00%
Jiuyun Yu Independent Non-Executive Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-05-20 Yifan Zhai Chief Medical Officer Derivative Exercise and Retained +92,746 --
2026-05-20 Dajun Yang Chairperson & CEO Derivative Exercise and Retained +95,575 --
2026-05-19 Yifan Zhai Chief Medical Officer Other Derivative Acquisition +616,546 $6.58–8.12
2026-05-19 Yifan Zhai Chief Medical Officer Other Derivative Acquisition +804,880 --
2026-05-19 Dajun Yang Chairperson & CEO Other Derivative Acquisition +616,546 $6.58–8.12
2026-05-19 Dajun Yang Chairperson & CEO Other Derivative Acquisition +804,880 --
2026-03-17 Jiuyun Yu Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Marc Lippman Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Marina S. Bozilenko Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 David Sidransky Lead Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Thomas Knapp General Counsel Initial Statement of Beneficial 0 --
2026-03-17 Shaomeng Wang Co-Founder, Chief Scientific Advisor & Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Yifan Zhai Chief Medical Officer Initial Statement of Beneficial 0 --
2026-03-17 Changqing Ye Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Dazhong Lu Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 HealthQuest Pharma Limited -- Initial Statement of Beneficial 0 --
2026-03-17 Dajun Yang Chairperson & CEO Initial Statement of Beneficial 0 --
2026-03-17 Wei Ren Independent Non-Executive Director Initial Statement of Beneficial 0 --
2026-03-17 Jin Cao Head of Finance Initial Statement of Beneficial 0 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Ascentage Pharma discussion 0 comments

Add a comment